Differentiating Scleroderma from other diseases
Scleroderma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating Scleroderma from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating Scleroderma from other diseases |
Risk calculators and risk factors for Differentiating Scleroderma from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating X from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
- [Disease name] must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||
Skin changes | Raynaud phenomenon | Dysphagia | Dyspnea | Impaired mobility | Edema (swelling) | Sclerodactyly | Telangiectasia | Impaired mobility | Autoantibodies | Blood indices | Nailfold video capillaroscopy | CT-scan | Imaging 3 | ||||||
Scleroderma | Limited cutaneous systemic sclerosis (CREST syndrome) | Skin thickening (induration) | + | + | +/- | +/- | + | + | Anti-centromere antibody
ANA |
Anemia | Nailfold microvascular changes | Chest CT showing evidence of pulmonary fibrosis | Nailfold microvascular changes | Interstitial lung disease / Pulmonary hypertension | |||||
Diffuse cutaneous systemic sclerosis | Skin thickening (induration) | + | + | +/- | +/- | +/- | + | + | +/- | Anti-Scl-70 antibody
ANA |
Anemia | Nailfold microvascular changes | |||||||
Systemic diseases | Scleredema
(Buschke's disease)[1] |
Skin thickening | - | - | - | + | + | - | - | + | - | - | - |
|
| ||||
Scleromyxedema
(lichen myxedematosus) |
Fibroblast proliferation in the dermis | ||||||||||||||||||
Amyloidosis | |||||||||||||||||||
Eosinophilic fasciitis | + | Eosinophilia (peripheral blood smear) | |||||||||||||||||
Chronic graft-versus-host disease | |||||||||||||||||||
Drug induced scleroderma | |||||||||||||||||||
Scleroderma overlap syndromes | Systemic lupus erythematosus | ||||||||||||||||||
Dermatomyositis | |||||||||||||||||||
Rheumatoid arthritis | |||||||||||||||||||
Endocrine disorders | Diabetes mellitus (diabetic cheiroarthropathy) | ||||||||||||||||||
Myxedema due to hypothyroidism | |||||||||||||||||||
POEMS syndrome | |||||||||||||||||||
Renal diseases | Nephrogenic systemic fibrosis |
References
- ↑ Rongioletti F, Kaiser F, Cinotti E, Metze D, Battistella M, Calzavara-Pinton PG, Damevska K, Girolomoni G, André J, Perrot JL, Kempf W, Cavelier-Balloy B (December 2015). "Scleredema. A multicentre study of characteristics, comorbidities, course and therapy in 44 patients". J Eur Acad Dermatol Venereol. 29 (12): 2399–404. doi:10.1111/jdv.13272. PMID 26304054.